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My story starts with the melanocyte, touches on psoralens
and extends to PUVA. Early in 1965 – I had just published
my description of ATPase in Langerhans cells (Wolff, 1963)
– Fitzpatrick appeared in Vienna out of a blue sky and to
my Chairman’s surprise he had not come to visit the
Department but to meet the third year dermatology resident
who had authored this paper. I had attracted Fitzpatrick’s
attention through William B. Reed, who by that time was
scanning Europe for young people interested in dermato-
logical research. Fitzpatrick’s interest in Langerhans cells
derived from the prevailing hypothesis that Langerhans cells
are effete melanocytes, and the presence of an enzyme like
ATPase was, of course, not compatible with the theory of a
dying or dead cell. At Fitz’s short stop-over in Vienna we
discussed melanin and melanocytes, and this three-hour
encounter, where he talked and I listened, influenced my
entire scientific career. The message was that dermatology,
in order to become a scientifically-based medical discipline,
had to go back to the basic sciences and acquire, step by
step, an understanding of skin disease on the basis of
cellular and molecular processes.
Through the identification in the 50s and early 60s of the
essential elements of melanin pigmentation, Fitzpatrick,
together with Aaron B Lerner and later with Makato Seiji,
had actually introduced cellular biology – although then not
known by this name – into dermatology: the first demon-
stration of tyrosinase in humans (Fitzpatrick et al, 1950) and
the isolation and characterization of the metabolic unit of
melanin pigmentation, the melanosome (Seiji et al, 1963). I
was particularly impressed by an experiment Fitzpatrick
and coworkers had performed which struck me by its
simplicity and ingenuity. In those days there was a
controversy about the origin of melanosomes. This was
mainly due to the fact that different groups of researchers
were working on cellular fractions derived from different
mouse melanomas, B-16, Cloudman S91 and Harding-
Passey, and those focusing on Harding-Passey always
found melanosomes, mitochondria, mitochondrial enzymes
and tyrosinase in the same fraction – concluding that
melanosomes derive from mitochondria. The experiment
performed by the Fitzpatrick group was to irradiate Harding-
Passey melanoma homogenates with UV and by doing
so induce melanin formation within melanosomes which
imparted on them a greater density and thus made it
possible to easily separate them from mitochondria by
density gradient centrifugation.
Fitzpatrick’s visit to Vienna reflected his unlimited
curiosity and his deep interest in people, particularly young
people. From this first encounter an increasingly close
exchange of ideas and – later – scientific collaboration
resulted and this, of course, initially focused on the
melanocyte and pigmentation. Enter PUVA. Since the early
50s Fitzpatrick had had a great interest in psoralens as a
means of increasing melanin pigmentation, but when he
remembered Allyn’s report at an Annual Academy of
Dermatology Meeting that psoriasis can be improved by
topical psoralens and ultraviolet light, our discussions also
switched to inflammatory diseases. This even led to some
experiments I performed on patients with psoriasis in
Vienna – in those days we didn’t need approval of ethical
committees and other regulatory agencies – which, how-
ever, were unsuccessful. I couldn’t show any efficacy, and
instead at times even induced severe phototoxic reactions.
The problem, of course, was that in those days no adequate
lighting equipment was available, oral psoralens were
difficult to obtain in Europe, and we had no idea how to
deal with the dosing problem. This convinced me that there
was no future in this approach.
I couldn’t believe my eyes when in April 1974, at a
meeting arranged by Jose´ de Moragas in Barcelona,
Fitzpatrick showed me photographs of patients in whom
psoriasis had been cleared by the combined treatment
with oral 8-methoxypsoralen and UVA. The secret of this
success was that John A. Parrish had managed to persuade
a lighting company to produce fluorescent tubes with a high
intensity output in the UVA range. Since these fluorescent
bulbs emitted no or only minimal amounts of UVB the
problem of under- or overdosing was overcome, by the
Harvard group, through pretherapy phototoxicity testing.
I was enthusiastic and agreed to a collaboration. A few
months later we were in possession of the fluorescent bulbs
used by Fitzpatrick, Parrish and Pathak and with the
financial help of Franz Greiter, an Austrian sunscreen
industrialist with a deep scientific interest in sun protection
and pigmentation, we enlisted the help of a Viennese
carpenter by the name of Werner Seliger and constructed
irradiation units that permitted us to embark on a crash
clinical trial of what was later called PUVA in psoriatic
patients. We followed the original Harvard protocol and
when the first PUVA results were published in The New
England Journal of Medicine in December 1974 (Parrish
et al, 1974), we had already accumulated close to 100
patients confirming the Harvard results (Wolff et al, 1975).
The PUVA success story is known. Tom Fitzpatrick,
John Parrish, Madhu Pathak and I toured the world
almost like salesmen promoting photochemotherapy. For
Fitzpatrick – who was the driving force and who had been
interested in psoralens since the 50s – this was a dream
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come true. Since Psoralens plus sunlight as repigmenting
mechanism dated back to ancient Egypt, Egyptian derma-
tologists, particularly AM El Mofty, took great pride in
inviting Fitzpatrick to lecture in Cairo. From one of these
trips ‘‘TBF’’ brought a ‘‘souvenir’’ of 500 grams of 5-methoxy-
psoralen to Europe. With the increasingly tough regulatory
rules in the United States and out of fear of failing to get this
whitish powder through US customs, he considered the
‘‘stuff’’ too difficult to handle. So he left it with me for further
use or to be discarded.
We had it chemically purified and after obtaining
permission from the Austrian regulatory agencies employed
it as a photosensitizing agent in a clinical trial of PUVA on
psoriatic patients showing equal efficacy but less toxicity
than 8-methoxypsoralen (Ho¨nigsmann et al, 1979). Although
never approved in the United States 5-methoxypsoralen is
widely used for photochemotherapy in Europe and else-
where. Again, Fitzpatrick was the initiator and driving force
behind a new therapeutic concept, as he had been with 8-
methoxypsoralen, photochemotherapy and the introduction
of b-carotene as an oral photoprotection agent in erythro-
poietic protoporphyria (Matthews-Roth et al, 1974).
Before the PUVA era Fitzpatrick’s influence on the
international scene had been mainly in the pigmentary field,
in his engagement in the melanoma issue – remember, with
Martin C. Mihm he had defined the early diagnostic signs for
melanoma (Mihm et al, 1973) – and as a clinician by creating
the dermatologic bible Dermatology in General Medicine.
PUVA-photochemotherapy, however, established him as
one of the global players beyond dermatology. All this
resulted in a large number of honorary memberships
conferred on him by National Societies of Dermatology
worldwide and the Certificate of Appreciation issued by the
International League of Dermatology which was awarded
for Life Long Commitment to Academic Dermatology and
for Seminal Scientific Contributions.
The name Thomas B. Fitzpatrick is associated with many
milestones: the melanosome and tyrosinase, the epidermal
melanin unit, skin phototypes, early markers of melanoma,
sun protection factors, vitiligo and, of course, PUVA
photochemotherapy. The landmark books Fitzpatrick’s
Dermatology in General Medicine and Color Atlas and
Synopsis of Clinical Dermatology are milestones in them-
selves. Fitzpatrick’s science was truly international in scope,
and so were his mentoring and collaborative relationships.
He had limitless enthusiasm, a unique sense of humor, he
was extremely curious and had a passion for perfection and
a great love of life. All this he imparted on his many
international friends and colleagues and, in particular, on the
many international fellows whom he hosted in his depart-
ment and whom he continued to mentor in their further
careers. The worldwide community of dermatoscientists
has acknowledged him as master and leader. He was
a towering personality and what he created in the 20th
Century is a challenge for the dermatosciences of the
future.
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